

Date: February 26, 2025

To,
Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers, 25th Floor,
Dalal Street, Mumbai – 400 001

To,
Listing Compliance Department
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor, Plot No. C/2, G
Block, Bandra Kurla Complex, Bandra (E),
Mumbai-400051

Scrip Code: 531146

SYMBOL: MEDICAMEQ

Dear Sir,

Subject: Outcome of the Meeting of Board of Directors of Medicamen Biotech Limited (“the Company”) in accordance with Regulation 30 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**Listing Regulations, 2015**”), we wish to inform your good office that the Board of Directors of the Company at their meeting held today i.e., **Wednesday, February 26, 2025**, has, inter alia, considered and approved the following businesses:

- I. The Preferential Issue of up to **13,00,000 (Thirteen Lakh) Equity Shares** of Face Value of Rs. 10/- each, for cash, at an issue price of Rs. 530/- determined in accordance with the provisions of Chapter V of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“**SEBI ICDR Regulations**”), for cash, for an aggregate amount of up to Rs. 68,90,00,000 /- (Rupees Sixty Eight Crore and Ninety Lakh Only), to below-mentioned persons/ entities belonging to “Non-Promoter” category, subject to the approval of members of the Company and applicable regulatory authorities:

Sr. No.	Name of the Proposed Allottees	Category (Promoter & Promoter Group/ Non-Promoter)	No. of Equity Shares (up to)
1.	Veralogix Holdings (PTY) Ltd	Non-Promoter	6,00,000
2.	Ginnerup Capital APS	Non-Promoter	5,00,000
3.	Eric Aarestrup Sorensen	Non-Promoter	1,50,000
4.	Ritesh Kantilal Oswal	Non-Promoter	50,000
TOTAL			13,00,000

Details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, with respect to the Preferential Allotment is enclosed as “Annexure A”.

- II. Preferential Issue of up to **6,55,000 (Six Lakh and Fifty Five Thousand) Fully Convertible Warrants (“Warrants”)**, at an issue price of Rs. 530/- per warrant, determined in accordance with the provisions of Chapter V of SEBI (ICDR) Regulations, convertible at the option of the Warrant Holder(s) in one or more tranches, within 18 (eighteen) months from the date of allotment into equivalent number of fully paid-up equity shares, for cash, for an aggregate amount of up to Rs. 34,71,50,000/- (Rupees Thirty Four Crore Seventy One Lakh and Fifty Thousand Only), to below-mentioned persons/entities belonging to “Promoter & Promoter Group” and “Non-Promoter” category, subject to the approval of members of the Company and applicable regulatory authorities:

Sr. No.	Name of the Proposed Allottees	Category (Promoter & Promoter Group/ Non-Promoter)	No. of Warrants (up to)
1.	Shivalik Rasayan Limited	Promoter & Promoter Group	5,00,000
2.	Gunavanth Kumar Neha	Non-Promoter	1,00,000
3.	Prithish Garg	Non-Promoter	50,000
4.	Arshiya Thapar	Non-Promoter	2,500
5.	Rahat Kapoor	Non-Promoter	2,500
TOTAL			6,55,000

Details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, with respect to the Preferential Allotment is enclosed as “Annexure B”.

- III.** Constitution of a Preferential Issue Committee to finalize/approve all the relevant documents, as may be deemed necessary.
- IV.** Approved the draft notice of Extra-Ordinary General Meeting to be held on Wednesday, March 26, 2025 at 12:00 Noon (IST) through Video Conferencing (VC)/ Other Audio-Visual Means (OAVM) facility, to seek approval of members of the Company.

The meeting of the Board of Directors commenced at 03.00 P.M. and concluded at 04.00 P.M.

You are requested to kindly take the same on your records.

Thanking You,
Yours Sincerely,
For **Medicamen Biotech Limited**

Parul Choudhary
Company Secretary & Compliance Officer

Annexure A

Details on Preferential Allotment in terms of SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024:

S. No.	Particulars	Disclosures																													
1.	Type of securities proposed to be issued	Equity Shares																													
2.	Type of issuance	Preferential Issue																													
3.	Total number of securities proposed to be issued or total amount for which the securities will be issued	Issue and allotment of up to 13,00,000 Equity Shares of the face value of Rs. 10/- (Rupees Ten Only) each, for cash, aggregating up to Rs. 68,90,00,000 /- (Rupees Sixty Eight Crore and Ninety Lakh Only), at an issue price of Rs. 530/- per Equity Share, determined in accordance with the provisions of Chapter V of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended and applicable provisions of Companies Act, 2013.																													
4.	Name and number of the Investor(s)	1. Veralogix Holdings (PTY) Ltd 2. Ginnerup Capital APS 3. Eric Aarestrup Sorensen 4. Ritesh Kantilal Oswal																													
5.	Post allotment of securities- outcome of the subscription	<table border="1"> <thead> <tr> <th rowspan="2">Name of Investors</th> <th colspan="2">Pre-Preferential</th> <th colspan="2">Post Preferential</th> </tr> <tr> <th>No. of Shares</th> <th>%</th> <th>No. of Shares</th> <th>%</th> </tr> </thead> <tbody> <tr> <td>Veralogix Holdings (PTY) Ltd</td> <td>0</td> <td>0.00</td> <td>6,00,000</td> <td>4.28</td> </tr> <tr> <td>Ginnerup Capital APS</td> <td>1,56,600</td> <td>1.23</td> <td>6,56,600</td> <td>4.69</td> </tr> <tr> <td>Eric Aarestrup Sorensen</td> <td>0</td> <td>0.00</td> <td>1,50,000</td> <td>1.07</td> </tr> <tr> <td>Ritesh Kantilal Oswal</td> <td>93,082</td> <td>0.73</td> <td>1,43,082</td> <td>1.02</td> </tr> </tbody> </table>	Name of Investors	Pre-Preferential		Post Preferential		No. of Shares	%	No. of Shares	%	Veralogix Holdings (PTY) Ltd	0	0.00	6,00,000	4.28	Ginnerup Capital APS	1,56,600	1.23	6,56,600	4.69	Eric Aarestrup Sorensen	0	0.00	1,50,000	1.07	Ritesh Kantilal Oswal	93,082	0.73	1,43,082	1.02
Name of Investors	Pre-Preferential			Post Preferential																											
	No. of Shares	%	No. of Shares	%																											
Veralogix Holdings (PTY) Ltd	0	0.00	6,00,000	4.28																											
Ginnerup Capital APS	1,56,600	1.23	6,56,600	4.69																											
Eric Aarestrup Sorensen	0	0.00	1,50,000	1.07																											
Ritesh Kantilal Oswal	93,082	0.73	1,43,082	1.02																											
6.	Issue price	Rs. 530/- per Equity Share																													
7.	In case of convertibles, Intimation on conversion of securities or on lapse of the tenure of the instrument.	Not Applicable																													
8.	Nature of Consideration (Whether cash or consideration other than cash)	Cash																													
9.	Any cancellation or termination of proposal for issuance of securities including reasons thereof.	Not Applicable																													

Annexure B

Details on Preferential Allotment in terms of SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024:

S. No.	Particulars	Disclosures				
1.	Type of securities proposed to be issued	Fully Convertible Warrants (Warrants)				
2.	Type of issuance	Preferential Issue				
3.	Total number of securities proposed to be issued or total amount for which the securities will be issued	Issue and allotment of up to 6,55,000 Fully Convertible Warrants (“Warrants”) of the face value of Rs. 10/- (Rupees Ten Only) each, carrying right exercisable by the Warrant holder to subscribe to one Equity Share of the face value of Rs. 10/- (Rupees Ten Only) each for cash, aggregating up to Rs. 34,71,50,000/- (Rupees Thirty Four Crore Seventy One Lakh and Fifty Thousand Only, at an issue price of Rs. 530/- per Warrant, determined in accordance with the provisions of Chapter V of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended and applicable provisions of Companies Act, 2013.				
4.	Name and number of the Investor(s)	<ol style="list-style-type: none"> 1. Shivalik Rasayan Limited 2. Gunavanth Kumar Neha 3. Prithish Garg 4. Arshiya Thapar 5. Rahat Kapoor 				
5.	Post allotment of securities- outcome of the subscription	Name of Investors	Pre-Preferential		Post Preferential (presuming full conversion of warrants)	
			No. of Shares	%	No. of Shares	%
		Shivalik Rasayan Limited	54,66,095	42.99	59,66,095	40.67
		Gunavanth Kumar Neha	0	0.00	1,00,000	0.68
		Prithish Garg	0	0.00	50,000	0.34
		Arshiya Thapar	50	0.00	2550	0.02
		Rahat Kapoor	0	0.00	2500	0.02
6.	Issue price	Rs. 530/- per Warrant				
7.	In case of convertibles, Intimation on conversion of securities or on lapse of the tenure of the instrument.	Up to 6,55,000 Warrants are convertible into equivalent number of Equity Shares of Rs. 10/- each within a maximum period of 18 months from the date of allotment of such Warrants. An amount equivalent to 25% of the warrant issue price shall be payable upfront on the date of the allotment of the warrant and the balance 75% shall be payable by the Allottee(s) on the				

MEDICAMEN Biotech Limited



Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

		exercise of option of conversion of the warrant(s). The number of equity shares to be allotted on exercise of the warrants shall be subject to appropriate adjustments as permitted under the rules, regulations and laws, as applicable from time to time.
8.	Nature of Consideration (Whether cash or consideration other than cash)	Cash
9.	Any cancellation or termination of proposal for issuance of securities including reasons thereof.	Not Applicable

Thanking You,
Yours Sincerely,
For Medicamen Biotech Limited

Parul Choudhary
Company Secretary & Compliance Officer